nach oben

Breast Cancer Research

Erschienen in:

01.12.2002 | Commentary

Estrogen–progestin replacement therapy: regulatory action needed

verfasst von: Malcolm C Pike, Ronald K Ross

Erschienen in: Breast Cancer Research | Ausgabe 6/2002

Einloggen, um Zugang zu erhalten

Abstract

It is now established that the most commonly prescribed estrogen–progestin replacement therapy regimen significantly increases breast cancer risk. What are the risks associated with other regimens? Studies with breast cancer as the outcome cannot answer these questions in the right timeframe. It is incumbent on us to agree that some intermediate marker of risk must be used to show the probable effect of a regimen. We should then act as if the effect on the marker is a quantitative guide to the probable effect on breast cancer risk. Regulatory authorities need to require such studies on all current regimens.

Schairer C: Progesterone receptors – animal models and cell signalling in breast cancer: implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Res. 2002, 4: 244-248. 10.1186/bcr540.CrossRefPubMedPubMedCentral

Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRef

Henderson BE, Pike MC, Ross RK, Mack TM, Lobo RA: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 1988, 49 (suppl): 9-15.

Key TJA, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988, 24: 29-43. 10.1016/0277-5379(88)90173-3.CrossRefPubMed

Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C: Combined oestrogen-progestogen replacement therapy and breast cancer risk [letter]. Lancet. 1992, 340: 1044-10.1016/0140-6736(92)93064-T.CrossRefPubMed

Shoupe D, Meme D, Mezrow G, Lobo RA: Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. N Engl J Med. 1991, 325: 1811-1812.CrossRefPubMed

Varila E, Wahlstrom T, Rauramo I: A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001, 76: 969-973. 10.1016/S0015-0282(01)02846-1.CrossRefPubMed

Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV: Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes. Fertil Steril. 1994, 62: 485-490.CrossRefPubMed

Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R: Transvaginal administration of progesterone. Obstet Gynecol. 1997, 90: 396-401. 10.1016/S0029-7844(97)00270-6.CrossRefPubMed

10.

Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR: Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol. 1994, 83: 693-700.PubMed

11.

Williams DB, Voigt BJ, Yao SF, Schoenfeld MJ, Judd HL: Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol. 1994, 84: 787-793.PubMed

12.

Pike MC, Ross RK: Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000, 65: 659-664. 10.1016/S0039-128X(00)00122-7.CrossRefPubMed

13.

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskaas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Ann Intern Med. 1999, 130: 262-269.CrossRefPubMed

Titel: Estrogen–progestin replacement therapy: regulatory action needed
verfasst von: Malcolm C Pike
Ronald K Ross
Publikationsdatum: 01.12.2002
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 6/2002
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr550

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Estrogen–progestin replacement therapy: regulatory action needed

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2002

Prolactin signaling and Stat5: going their own separate ways?

The importance of being a myoepithelial cell

Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

Expression and prognostic significance of lysozyme in male breast cancer

Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer

Mutations in DNA damage response genes and breast cancer susceptibility

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie